US20090325263A1 - Preparation of glassified biological reagents - Google Patents
Preparation of glassified biological reagents Download PDFInfo
- Publication number
- US20090325263A1 US20090325263A1 US12/439,274 US43927407A US2009325263A1 US 20090325263 A1 US20090325263 A1 US 20090325263A1 US 43927407 A US43927407 A US 43927407A US 2009325263 A1 US2009325263 A1 US 2009325263A1
- Authority
- US
- United States
- Prior art keywords
- reagent
- well
- dried
- reagents
- biological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 172
- 238000002360 preparation method Methods 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 104
- 239000000463 material Substances 0.000 claims abstract description 32
- 238000007496 glass forming Methods 0.000 claims abstract description 24
- 239000000945 filler Substances 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000001035 drying Methods 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 239000000243 solution Substances 0.000 claims abstract description 12
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 34
- 230000003321 amplification Effects 0.000 claims description 23
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 23
- 239000004793 Polystyrene Substances 0.000 claims description 21
- 229920002223 polystyrene Polymers 0.000 claims description 21
- 238000003753 real-time PCR Methods 0.000 claims description 19
- 238000003556 assay Methods 0.000 claims description 17
- 239000000377 silicon dioxide Substances 0.000 claims description 17
- 229910052751 metal Inorganic materials 0.000 claims description 13
- 239000002184 metal Substances 0.000 claims description 13
- 238000003860 storage Methods 0.000 claims description 13
- 238000013412 genome amplification Methods 0.000 claims description 10
- 238000007789 sealing Methods 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 7
- 230000035897 transcription Effects 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 5
- 230000002035 prolonged effect Effects 0.000 claims description 4
- 238000004166 bioassay Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 33
- 238000009472 formulation Methods 0.000 description 27
- 239000011324 bead Substances 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 239000000839 emulsion Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 11
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 11
- 239000012807 PCR reagent Substances 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000002274 desiccant Substances 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000012456 homogeneous solution Substances 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000013065 commercial product Substances 0.000 description 3
- -1 deoxynucleotides Chemical group 0.000 description 3
- 230000009477 glass transition Effects 0.000 description 3
- 238000012804 iterative process Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 238000011990 functional testing Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000012931 lyophilized formulation Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000701844 Bacillus virus phi29 Species 0.000 description 1
- 101000693922 Bos taurus Albumin Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 150000003944 halohydrins Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
- B01L3/50851—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates specially adapted for heating or cooling samples
Definitions
- This invention relates to the long-term storage of biological materials and reagents in a glassy, porous state.
- it relates to methods of making these materials and reagents using a multi-well plate and the storage thereof.
- biologically active materials are sufficiently stable so that they can be isolated, purified, and then stored in solution at room temperature.
- biological reagents are stored in a glycerol solution which is maintained at temperatures of 4° C., ⁇ 20° C., or ⁇ 70° C. They may be stored in bulk and then combined with other reagents before use.
- One type of carrier or filler which has been used to stabilize biological reagents is glass-forming filler materials.
- the biological reagent solutions are incorporated into the glass-forming filler materials (which are water soluble or a water-swellable substance). They are then dried to produce a glassy composition which immobilizes and stabilizes the biological reagent.
- glass-forming filler materials for stabilizing biological reagents see U.S. Pat. No. 5,098,893; U.S. Pat. No. 5,200,399 and U.S. Pat. No. 5,240,843.
- Carbohydrates such as glucose, sucrose, maltose or maltotriose are an important group of glass-forming substances.
- Other polyhydroxy compounds can be used such as carbohydrate derivatives like sorbitol and chemically modified carbohydrates.
- Another important class of glass-forming substances are synthetic polymers such as polyvinyl pyrrolidone, polyacrylamide, or polyethyleneimine.
- glass-forming substances include sugar copolymers such as those sold by GE Healthcare under the registered trademark FICOLLTM.
- FICOLLTM has molecular weights of 5,000 to 1,000,000 and contains sucrose residues linked through ether bridges to bifunctional groups (U.S. Pat. No. 3,300,474).
- groups may be an alkylene of 2, 3 or more carbon atoms but not normally more than 10 carbon atoms.
- the bifunctional groups serve to connect sugar residues together.
- These polymers may, for example, be made by reaction of sugar with a halohydrin or bis-epoxy compound.
- Stabilized biological materials in a glassy matrix of carbohydrate polymers can be prepared, either by freeze-drying (Treml et al. U.S. Pat. No. 5,593,824; Franks and Hatley U.S. Pat. No. 5,098,893) or by vacuum drying (Walker et al. U.S. Pat. No. 5,565,318).
- freeze-drying Teml et al. U.S. Pat. No. 5,593,824; Franks and Hatley U.S. Pat. No. 5,098,893
- vacuum drying Walker et al. U.S. Pat. No. 5,565,318.
- These water-soluble reagents are convenient to use for complex molecular biology applications. This approach is particularly useful for reagent systems composed of enzymes, nucleotides and other components dispensed in single-use aliquots. Reconstitution of the glassy matrix delivers buffered enzymes for applications including DNA amplifications and DNA sequencing.
- a method of making a dried reagent preparation comprises the steps of: providing an aqueous solution of at least one buffered biological reagent; mixing a glass forming filler material with the buffered reagent solution to form a mixture wherein the concentration of the filler material is sufficient to facilitate formation of a glassy, porous composition; dispensing a predetermined amount of the mixture into wells of a multi-well container; drying the mixture in the container to form the dried reagent preparation; wherein the reagent preparation is water soluble and has a Tg sufficient for room temperature stability.
- the mixture is preferably a homogeneous solution.
- the dried reagent preparation is collected into a reagent bottle for prolonged room temperature storage.
- the dried reagents are stored in the multi-well container, with the top of the container sealed with a sealing tape for prolonged storage.
- the sealing tape is heat-activated.
- the multi-well container according to the invention can be a silica mould or a polystyrene plate.
- the invention further comprises placing the polystyrene plate on a metal mould prior to lyophilizing, so that the outside wall of each well of the polystyrene plate is in close contact with a well of said metal mould for efficient heat transfer. We discovered that this improves the drying process and produces dried reagents of improved integrity.
- the present invention provides a dried biological reagent composition made according to the above methods.
- the reagent composition made according to the invention is water soluble and has a T g sufficient for room temperature stability.
- the reagent composition has structural integrity.
- the biological reagent composition is capable of completely dissolving in 25 ⁇ l of aqueous solution in less than 1 minute, preferably 30 seconds.
- the reagent composition preferably has a moisture content of less than 10%.
- the reagent composition may have at least one reagent which is unstable when alone in an aqueous solution at room temperature.
- the reagent composition may also comprise a plurality of reagents which may or may not react with each other when in aqueous solution at room temperature.
- FIG. 1 shows a process work-flow of the method for making a dried reagent preparation according to an embodiment of the invention.
- FIG. 2 shows from the top left: a 384-well polystyrene plate that is used in the method of making a dried reagent preparation according to an embodiment of the invention
- top right standard curve showing different amounts of lambda DNA as template with starting concentration of 10 million copies to 1000 copies including a no template control
- bottom left dried reagent preparation cake/cube made from the 384-well polystyrene plate, stored in a plastic bottle
- bottom right the amplification plot showing that the dried reagent preparation is successfully used in the Lambda DNA real-time qPCR amplification reactions.
- FIG. 3 shows from the top left: a 96-well silica mould that is used in the method of making a dried reagent preparation according to an embodiment of the invention
- top right standard curve showing different amounts of lambda DNA as template with starting concentration of 10 million copies to 1000 copies including a no template control
- bottom left dried reagent tablets made from the 96-well silica mould, stored in a plastic bottle
- bottom right the amplification plot showing that the dried reagent preparation is successfully used in the Lambda DNA real-time qPCR amplification reactions.
- FIG. 4 shows a 96-well PCR plate containing PCR formulation goes into a metal holder before lyophilizing.
- FIG. 5 shows room temperature stable PCR reagents made according to an embodiment of the invention in different formats.
- Top left dried PCR mix in a bottle.
- Top right dried PCR mix in 96-well plate.
- Bottom left dried PCR mix in 384-well plate.
- Bottom right dried PCR mix in 96-well perforated plate.
- FIG. 6 shows stability of dried PCR reagents made according to an embodiment of the invention.
- Dried PCR mix was used for qPCR of Lambda DNA. Similar performance was noticed with (1) the ‘wet’ formulation bead mix (upper left), (2) dried cakes made using current protocol (upper right), and (3) PURE TAQ READY-TO-GOTM (RTG) PCR beads from GE Healthcare (lower left). Lower right: Ct values and PCR efficiency for the above mentioned three reactions in triplicates. Both the Ct values and PCR efficiency values of the new format and the puRe Taq RTG beads are comparable.
- FIG. 7 shows stability of dried PCR reagents made according to an embodiment of the invention.
- Dried PCR mix was stored at 40° C. and Room Temperature (RT) for 8 days.
- the dried reagents were used for qPCR of Lambda DNA, with similar performance.
- Top left dried PCR reagent cakes stored at RT.
- Top right dried PCR reagent cakes stored at 40° C.
- FIG. 8 shows Ct values and PCR efficiency for the above mentioned four reactions in duplicates. Both the Ct values and PCR efficiency values of the current format and the puRe Taq RTG beads are comparable at 40° C. and room temperature.
- FIG. 9 shows the results of real-time PCR reactions according to one example of the invention.
- Upper left panel real-time PCR using lyophilized reagents including the TaqMan primers and probe.
- Lower left panel Lyophilized reagent control (TaqMan primers and probe were not lyophilized, other reagents were lyophilized as in Example 1).
- Upper right panel Commercial puRe Taq RTG bead control (All the other reagents were not lyophilized). When puRe Taq RTG reactions were used to make a standard curve while treating all other reactions as unknowns the reactions with equivalent amounts of template DNA fell on the standard curve (Lower right panel, “X” denotes the “unknowns”).
- FIG. 10 shows that the Phi29 DNA polymerase is stable in the lyophilized form.
- Whole genome amplification assay using either lyophilized reagent or the “wet” mixture was performed. Robust amplification was detected, even with lyophilized reagent that had been stored at 40° C. for 35 days.
- FIG. 11 shows successful transcription of a DNA template using lyophilized IVT reagent (A, B, C) as compared to conventional “wet” kit (Roche IVT). ntc: no template control.
- the biological reagent compositions of the present invention are particularly suitable for performing a wide variety of analytical procedures which are beneficially or necessarily performed on blood plasma or diluted plasma.
- the analytical procedures will generally require that the blood plasma be combined with one or more reagent spheres so that some optically detectible change occurs in the plasma which may be related to measurement of a particular component or characteristic of the plasma.
- the plasma will undergo a reaction or other change which results in a changing color, fluorescence, luminescence or the like, which may be measured by conventional spectrophotometers, fluorometers, light detectors, etc.
- immunoassays and other specific binding assays may be performed.
- a still further category of biological reagents to which the present invention is applicable is protein and peptides, including derivatives thereof such as glycoproteins.
- proteins and peptides may be any of: enzymes, transport proteins (for example hemoglobin, immunoglobulins, hormones, blood clotting factors and pharmacologically active proteins or peptides).
- nucleosides such as deoxynucleotides, ribonucleotides and dideoxynucleotides
- dinucleotides oligonucleotides
- enzyme cofactors whether or not these are nucleotides.
- Enzyme substrates in general are also biological reagents to which the invention may be applied.
- the biological reagent for stabilization in storage may be isolated from a natural source, animal, plant, fungal or bacterial, or may be produced by and isolated from cells grown by fermentation and artificial culture. Such cells may or may not be genetically transformed cells.
- Another development of this invention is to store more than one reagent of a reacting system in a glass reagent sphere. This can be useful for materials which will be required to be used together in, for example, an assay or a diagnostic kit.
- reagents may be mixed together in an aqueous emulsion and then incorporated together into a glass. Alternatively, they may be incorporated individually into separate glasses which are then mixed together.
- one or more of the reagents may be a protein, peptide, nucleoside, nucleotide, or enzyme cofactor. It is also possible that the reagents may be simpler species. For instance, a standard assay procedure may require pyruvate and NADH to be present together. Both can be stored alone with acceptable stability. However, when brought together in an aqueous solution they begin to react. If put together in required proportions in the glassy reagent sphere, they do not react and the glass can be stored. By react we mean any biochemical reaction.
- the preferred biological reagents of the present invention are enzymes and cofactors that provide a reagent system to detect, amplify, modify or sequence nucleic acids.
- enzymes include but are not limited to DNA polymerases (e.g. Klenow), T7 DNA polymerase or various thermostable DNA polymerases such as Taq DNA polymerase; AMV or murine reverse transcriptase, T4 DNA ligase, T7, T3, SP6 RNA polymerase, Phage Phi29 DNA polymerase, and restriction enzymes.
- Cofactors include nucleotides, oligonucleotides, DNA, RNA, required salts for enzyme activity (e.g. magnesium, potassium and sodium), and salts required for buffer capacity. Buffer salts provide a proper pH range and aid stability. Some buffers which may be used include Tris pH 7.6-8.3.
- Any potential biological reagents may be evaluated using a protocol according to Example 1, infra.
- suitable biological reagents are rendered stable in the reagent sphere as determined by a functionality test like that in Example 1.
- glass forming filler materials which may be used in the present invention include carbohydrates such as FICOLLTM, sucrose, glucose, trehalose, melezitose, DEXTRANTM, and mannitol; proteins such BSA, gelatin, and collagen; and polymers such as PEG and polyvinyl pyrrolidone (PVP).
- the glass forming filler materials are preferably FICOLLTM polymer, BSA, sucrose, DEXTRANTM, or combinations thereof.
- a most preferred glass forming filler material for use in the present invention is FICOLLTM polymer.
- the formulation of a high viscosity mixture of biological reagent, glass forming filler material, and water is determined by an iterative process. First, one determines final as used concentrations desired of the system. The concentrations are normally stated in terms of molarity. Each biological reagent may have different formulations. Secondly, these concentrations are converted to a weight/dose basis for solids and a volume/dose basis for liquids.
- the mixture will dry hard and glassy if the glass forming material is allowed to go into solution.
- the desired mixture is an emulsion rather than a solution.
- emulsion we mean a saturated mixture such that two phases, solid and liquid, are present.
- the present invention is a semi-emulsion of a glass forming filler material in a biological reagent/buffer solution. The presence of the solids gives the emulsion an opaque to white color. A high viscosity emulsion still forms a glass when dried, but pores are available on the surface for water to move through and speed dissolution of the dried reagent preparation. The emulsion should have a white color.
- porosity we mean that the dried reagent preparation contains pockets of air bubbles which assist in the dissolution of the preparation. A preferred porosity would allow the preparation to dissolve in about 2 minutes or less.
- Another version of the invention provides a mixture of glass forming filler material and a biological reagent/buffer solution which is characterized as being a semi-emulsion.
- a semi-emulsion By this we mean a mixture having at least some properties of an emulsion.
- the semi-emulsion of the present invention may be formed by using the above iterative process to arrive at a solids concentration of about 10% to about 50%. The semi-emulsion can then be dispensed and dried to form the dried reagent preparation.
- any potential glass forming material may be evaluated using a protocol according to the iterative process described above.
- a suitable glass forming material produces a reagent preparation having an acceptable hardness, size, shape, T g , porosity, solubility, and stability.
- multi-well containers for making the dried reagent preparation include a polystyrene plate, a silica mould, or the like.
- the multi-well plate is one that has a standard dimension and layout that enables to use standard thermal cyclers for applications like PCR.
- the multi-well containers comprise two regions, a well field and a border.
- the border can be of any dimension, shape, or thickness, but preferably forms a multi-well platform with outer dimensions that are similar to those of a standard 96- or 384-well commercial microtiter plate, whose dimensions are approximately 85.5 mm in width by 127.75 mm in length.
- the plate contains a number of hollows arranged in a grid. These hollows are known as wells and act as reaction vessels for individual reactions, or storage containers for individual samples. Wells will be arranged in two-dimensional linear arrays on the multi-well platform. However, the wells can be provided in any type of array, such as geometric or non-geometric arrays. The number of wells can be a multiple of 96 within these ranges, preferably the square of an integer multiplied by 96.
- a 96-well plate has twelve columns and eight rows with 9 mm spacing between the centers of adjacent wells.
- a 384-well plate has twenty-four columns and sixteen rows with 4.5 mm spacing between the centers of adjacent wells.
- a 1536-well plate has forty-eight columns and thirty-two rows with 2.25 mm spacing between the centers of adjacent wells.
- Microtiter plates constituting one half of the above format are also in use. Also available are strips of wells that have similar spacing between the centers of adjacent wells. Multi-well containers having these dimensions can be compatible with robotics and instrumentation, such as multi-well platform translocators and readers as they are known in the art.
- the materials for manufacturing the multi-well platform will typically be polymeric, since these materials lend themselves to mass manufacturing techniques.
- polymers are selected that are known to have low fluorescence or other properties.
- Various methods in the art can be used to confirm that selected polymers possess the desired properties.
- Polymeric materials can particularly facilitate plate manufacture by molding methods known in the art and developed in the future, such as insert or injection molding.
- silica moulds in a 96-well and 384-well formats are silica moulds in a 96-well and 384-well formats. As shown in the Examples infra, a 96-well perforated silica molded plate can be used for dispensing and lyophilizing the reagents. The advantage here is the dried reagents should be easily removed from the mould after lyophilization.
- a typical formulation (using DNA labeling formulation as the example) is made as follows:
- All reagents used are typically autoclaved or filter sterilized (preferably a 0.25 ⁇ m filter) before use. Formulations are made and stored on ice until dispensed. For 200 mls (enough for 20,000 single dose preparation) of a DNA labeling formulation, 15 g each of FICOLLTM 400 and FICOLLTM 70 and 20 g melezitose are added to approximately 90 ml of sterile water and mixed on a stir plate until dissolved.
- a 20 ⁇ concentrated DNA labeling buffer 200 mM Tris pH 7.5, 200 mM MgCl 2 1M NaCl
- 10 mls of a 10 mg/ml BSA solution 50 ml of a 20 ⁇ concentrated DNA labeling buffer (200 mM Tris pH 7.5, 200 mM MgCl 2 1M NaCl) is added along with 10 mls of a 10 mg/ml BSA solution.
- 100 mM ATP, GTP, and TTP 100 mM ATP, GTP, and TTP are added.
- 400 Ku of Klenow fragment DNA polymerase is added (minimum concentration of stock should be 100 Ku/ml in order to keep the glycerol concentration below 1% in the final preparation).
- 1200 A 260 Units of d(N) 9 primer is added.
- the primer Before adding to the formulation, the primer should be heated at 65° C. for 7 minutes and quickly cooled on ice. After addition of the enzyme and primer, the final volume should be brought to 200 ml with sterile water. The density of the final solution will be 1.14 g/ml.
- the final volume per dose dispensed of the reagent homogeneous solution is often small, such as 5-30 ⁇ l, preferably 10 ⁇ l, to allow a working volume of 10-100 ⁇ l when the reagent preparation is dissolved in a working solution.
- a predetermined amount of homogeneous solution is dispensed into each well of a multi-well container, typically using a liquid dispensing robot (96 well/384 well pins).
- the solution is dispensed in a volume ranging from 4 ⁇ l to 20 ⁇ l but preferably 10 ⁇ l.
- the sample dispensed can be dried by freeze-drying or lyophilization.
- a suitable drying program produces a reagent preparation having an acceptable hardness, size, shape, T g , porosity, solubility, and stability.
- a preferred method of drying is by way of lyophilization.
- the dispensed reagents are successfully dried in a 96- or 384-well polystyrene plate.
- the drying process works better and no foam or flakes of the dried reagent observed compared to the plates dried without metal holders ( FIGS. 1 and 4 ).
- Direct contact of the outside wall of a polystyrene well (tube) with the metal well of the metal plate holder indirectly enhances the metal shelf contact area, which in turn achieves a better heat transfer to the samples.
- a silica mould on the other hand, has a thick wall and flat bottom for each well, and the lyophilization process in a silica mould works reasonably well without the use of a metal holder. This is probably due to the better contact of the mould with the freeze-dryer shelf and the heat transfer properties of the silica.
- a preferred lyophilization profile is shown below in Tables 2. Note that the samples are frozen in the freeze-drier for 1 hour at ⁇ 46° C. before running the following program.
- the single-dose format (bead or cake) can contain the pre-dispensed buffer, salt, detergent and nucleotide, etc. needed for the specific assay, in which the molecules are used.
- These enzymes and combinations can be used for a variety of molecular biology applications, including but not limited to PCR, RT-PCR, real time PCR, whole genome amplification, in vitro transcription and cDNA synthesis applications.
- the method eliminated the need to freeze drop the reagent mix into liquid nitrogen or onto a cold surface, yet the dried reagents maintain good structural integrity.
- the method has fewer steps in the manufacturing process.
- the dried reagent preparations can be stored in the plates or moulds directly when properly sealed and this significantly reduces the manufacturing and packaging costs.
- the dried reagents can be removed from silica moulds as tablets and from polyfiltronics 96-well plates as cubes and stored in sealed containers, i.e. capped bottles.
- Sealing of the plate or mould can be achieved by: lid, tape, heat activated tape etc.
- sealing of the plates is achieved by heat activation sealing using AbGene's Thermo-Seal and Easy-Peel sheets.
- a reagent preparation of the present invention is room temperature stable.
- room temperature stable we mean that the preparation can be stored at 22° C. for greater than 6 months with less than 20% loss of enzymatic activity as compared to the activity measured after the reagents are first dried.
- a reagent preparation of the present invention has a glass transition temperature (T g ) of at least 10° C.
- T g glass transition temperature
- a typical T g of the reagent preparation is 40° C.
- a T g of at least 40° C. will guarantee stability at room temperature (22° C.).
- a preferred T g is 45° C.
- the glass transition temperature is the temperature above which the viscosity of a glassy material drops rapidly and the glassy material turns into a rubber, then into a deformable plastic which at even higher temperatures turns into a fluid.
- the glass transition temperature is used as an important indicator of stability of the preparation. At temperatures below or near the T g the sample remains as a stable glass. As the temperature rises above the T g , the sample becomes a rubber and is less stable.
- the T g is measured using differential scanning calorimetry. 2-5 mg (1-2 spheres crushed) of sample are put into an aluminum pan. The T g of the sample is determined by subjecting the sample to a controlled temperature program from 0° C. to 100° C. at a rate of 10° C./min. The heat flow to and from the sample is measured and expressed as a shift in the baseline. The T g is expressed as the temperature at the midpoint of this baseline shift.
- a typical porosity will allow dissolution of the sphere in 20 ⁇ l of water in 1 minute or less.
- a preferred porosity will allow dissolution in 30 seconds or less.
- the manufacturing process is greatly simplified.
- the reagent mixture is dispensed directly into wells of a multi-well plate, which has a standard format as the commercial microtiter plate. This eliminated the need to freeze the reagent droplets in liquid nitrogen or on a cold surface.
- the dispensed mixture is then frozen, lyophilized in the well, and can be stored in the well too. This eliminated the need of moving the beads or the cakes from a drying pan into a storage container. Because the dried composition can be stored in the multi-well plate, the composition can be used in a subsequent workflow that is automated. Robotic systems can be used for processing the plates.
- compositions made are stable at ambient temperature. This saves cost on shipping (no dry-ice shipping), eliminates the need for freezer storage and shortens the reagent preparation time (no thawing). It offers convenience for the subsequent user. Most of the assay-related components could be pre-dispensed and stabilized into the single dose format. It saves the user time and plastic consumable costs for preparing the reagents master mix. It also offers increased reproducibility and reliability, as it reduced risk of contamination and errors.
- the composition is prepared with pre-dispensed reactions. This minimizes sample handling and pipetting steps, thus reducing the risk of contamination and pipetting errors by the user.
- the biological reagent formulation in this case, a reagent mixture for PCR is prepared according to standard protocol.
- the formulation of the 10 ⁇ l sphere contains 25 mM Tris-HCl (pH 9.0 at room temperature), 125 mM KCl, 3.75 mM MgCl2, 0.5 mM dNTP's, 0.6 mg/ml BSA, 3.5 units of rTaq DNA polymerase, and the glass-forming filler material comprising synthetic polymers FICOLLTM 400 (6.25%), FICOLLTM 70 (6.25%) and the secondary carbohydrate Melezitose (10%). All reagents are typically autoclaved or filter sterilized before use.
- Formulations are made and stored on ice until mixed and dispensed into polystyrene plates or silica moulds.
- Final formulation consists of glass forming filler material, BSA, dNTPs, and rTaq DNA polymerase and salts as described above.
- the final volume per dose of the reagent homogeneous solution was 10 ⁇ l. This allowed a working volume for PCR of 25 ⁇ l.
- the reagent was dispensed using an automatic pipette into a 384-well polystyrene plate.
- the 384-well plate was placed on top of the pre-cooled ( ⁇ 46° C.) Vertis freeze-dryer shelf for about 60 minutes to freeze the reagents.
- the frozen reagents were then subjected to the primary and subsequent secondary drying processes, according to the process described in Table 2 supra.
- the plate containing the dried reagents was stored in a re-sealable pouch containing desiccant as an integrated package by simply covering the plate with an adhesive cover or lid or a thermo seal.
- the dried reagents were removed from the plate as dried reagent tablets or cubes and were stored in a bottle and the bottles were stored in re-sealable pouch containing desiccant.
- Stability of the dried reagent composition was tested by real-time PCR amplification of Lambda DNA and comparing the amplification profile with that of commercial product (puRe Taq RTG beads; GE Healthcare).
- the primers used for the testing are SEQ ID NO: 1 (5′-GGT TAT CGA AAT CAG CCA CAG CGC C-3′) and SEQ ID NO: 2 (5′-GAT GAG TTC GTG TCC GTA CAA CTG G-3′).
- the real-time PCR amplification results are shown in FIG. 2 .
- a 384-well polystyrene plate is shown on the upper left side, which was used for making the dried reagent composition.
- the dried reagent tablets were stored in a plastic bottle (bottom left side) and stored at room temperature for about a week in a resalable pouch containing the desiccant.
- a 384-well plate containing the dried reagents is shown on the upper left side and is covered with the adhesive seal.
- the standard curve of different dilutions of lambda DNA template is shown on the upper right side.
- the real-time amplification curves of different dilutions of lambda DNA is shown on the bottom right side.
- the biological reagent formulation and the glass-forming filler material are prepared and mixed together according to Example 1.
- About 20 ⁇ l reagent mixture was dispensed using an automatic pipette into a 96-well silica mould ( FIG. 3 , upper left side).
- the silica mould was placed in a pre-cooled ( ⁇ 46° C.) Vertis freeze-dryer for about 60 minutes to freeze the reagents.
- the frozen reagents were then subjected to the primary and subsequent secondary drying processes, according to the process described in Table 2 supra.
- the dried reagents could be stored in the mould as an integrated package by simply covering the mould with an adhesive seal and by placing the plate in aluminum pouch containing desiccant. Alternatively, the dried reagents were removed from the mould as dried reagent cakes and were stored in a bottle containing desiccant.
- a 96-well silica mould is shown on the upper left side, which is used for making the dried reagent composition.
- the dried reagent cubes were stored in a plastic bottle (bottom left side) for a week in a re-sealable pouch containing the desiccant before performing the lambda DNA functional test.
- the standard curve of different dilutions of lambda DNA template is shown on the upper right side.
- the real-time PCR amplification plots of the different dilutions of lambda is shown on the bottom right side.
- the biological reagent formulation and the glass-forming filler material were prepared and mixed together according to Example 1.
- 10 ⁇ l reagent mixture was dispensed using an liquid dispensing robot ( FIG. 1 , bottom left side).
- the 96-well plate was placed on a 96-well metal holder ( FIG. 4 ).
- the 96-well plate with the metal holder was placed on top of the pre-cooled ( ⁇ 46° C.) Vertis freeze-dryer shelf for about 60 minutes to freeze the reagents.
- the frozen reagents were then subjected to the primary and subsequent secondary drying processes, according to the process described in Table 2 supra.
- the dried reagents could be stored in the 96-well plate as an integrated package by simply covering the plate with an adhesive seal or a lid or a thermoseal with the help of a heat sealer.
- Lambda DNA real-time PCR functional test was performed with the freshly prepared “wet” formulation and the dried reagents along with puRe Taq RTG beads.
- the sealed plates were stored at room temperature or in a 40° C. incubator for 8 days in a pouch containing desiccant. Stability of the dried reagent composition was tested by real-time PCR amplification of Lambda DNA (according to Example 1) and comparing the amplification profile with that of commercial product (puRe Taq RTG beads; GE Healthcare). The results are shown in FIGS. 6 , 7 and 8 .
- FIG. 6 shows Lambda qPCR with 96-well dried PCR cakes and comparison with the ‘wet’ formulation and the puRe Taq RTG beads.
- the figure shows stability of dried PCR reagents made according to an embodiment of the invention. Real-time PCR amplifications were performed with different concentrations of Lambda DNA starting from 10 million copies to 10 copies as template along with a no template control. Similar performance in terms of Ct values and PCR efficiency (bottom left table) was noticed with current format (upper right), puRe Taq RTG beads (lower left) and the ‘wet’ formulation (upper left).
- FIG. 7 shows stability of dried PCR reagents made according to an embodiment of the invention.
- Dried PCR mix was stored at 40° C. or Room Temperature (RT) for 8 days, then used for qPCR of Lambda DNA.
- the reagent made according to present invention achieved similar performance, as compared to commercial puRe Taq RTG bead.
- Top left dried PCR reagent cakes stored at RT.
- Top right dried PCR reagent cakes stored at 40° C.
- FIG. 8 shows the Ct values and the PCR efficiency for the current format reagents and the puRe Taq RTG beads at room temperature and 40° C.
- Real-time PCR is become an increasingly popular assay platform for gene expression analysis.
- One method for detection of amplified product in real time PCR utilizes a dual labelled single stranded (ss) DNA probe that is homologous to a specific portion of the template.
- the fluorescent modifications on this probe serve as a reporter (FAM) and quencher (TAMRA).
- FAM reporter
- TAMRA quencher
- the probe anneals to the template but does not emit fluorescent signal because of close proximity of the reporter dye to the quencher dye.
- Taq DNA polymerase amplifies DNA from the template the 5′-3′ exonuclease activity of the enzyme cleaves the labelled probe annealed to the template, releasing the quencher dye allowing for the reporter to fluoresce.
- the fluorescent signal is then recorded by the real time instrument.
- the formulation used to make a 2.5 ⁇ concentrated formulation for assaying ⁇ -actin includes: 25 mM Tris pH 9, 125 mM KCl, 3.75 mM MgCl 2 , 0.6 mg/ml BSA, 0.5 mM dNTPs, 0.25 U/ ⁇ l rTaq, 0.05% Tween 20, 0.05% NP-40, 1.5 ⁇ M ⁇ -actin Fwd primer (SEQ ID NO: 3: 5′-TCA CCC ACA CTG TGC CCA TCT ACG A-3′), 1.5 ⁇ M ⁇ -actin Rev primer (SEQ ID NO: 4: 5′-CAG CGG AAC CGC TCA TTG CCA ATG G-3′), 1 ⁇ M ⁇ -action probe (SEQ ID NO: 3: 5′-TCA CCC ACA CTG TGC CCA TCT ACG A-3′), 1.5 ⁇ M ⁇ -actin Rev primer (SEQ ID NO: 4: 5′-CAG CGG AAC CGC T
- FIG. 9 shows the results of these reactions.
- Upper left panel real-time PCR using lyophilized reagents including the TaqMan primers and probe.
- Lower left panel Lyophilized reagent control (The primers and probe were not included in the lyophilized formulation, but added prior to the real-time PCT reaction).
- Upper right panel Commercial puRe Taq RTG bead control (All the other reagents were not lyophilized). All reactions produced equivalent amplification profiles, R 2 values and slopes. When puRe Taq RTG reactions were used to make a standard curve while treating all other reactions as unknowns the reactions with equivalent amounts of template DNA fell on the standard curve (Lower right panel). Our results demonstrate that TaqMan primers and probe are amenable to RTG incorporation.
- Phi29 DNA polymerase is widely used for whole genome amplification as well as rolling circle amplification. We lyophilized this enzyme in a formulation that enables whole genome amplification. Our analyses demonstrate that the lyophilized formulation has the same activity as the “wet” formulation in performing whole genome amplification.
- GENOMIPHITM HY High Yield DNA amplification kit (GE Healthcare) contains all the components necessary for whole genome amplification by isothermal stand displacement amplification.
- the starting material for GENOMIPHITM reactions can be purified DNA or non-purified cell lysates. Microgram quantities of DNA can be generated from nanogram amounts of starting material in only a few hours. Typical DNA yields from a GENOMIPHITM HY reaction are 40-50 ⁇ g per 50 ⁇ l reaction, with an average product length of greater than 10 kb. DNA replication is extremely accurate due to the proofreading 3′-5′ exonuclease activity of the enzyme.
- GENOMIPHITM reaction mixture was prepared including Phi29 DNA polymerase, random hexamers, dNTPs and the GENOMIPHITM HY reaction buffer along with the stabilizers FICOLLTM 70, FICOLLTM 400, Melezitose and BSA, as a 2 ⁇ mix. Ten ⁇ l volume aliquots of the mixture were dispensed into 12-well PCR strip tubes. The dispensed products were lyophilized as a cake using VirTis freeze-drier. The dried products were stored at either room temperature or at 40° C. for 35 days. Whole genome amplification was successfully performed with these products using as low as 10 ng of human genomic DNA. This was compared with whole genome amplification using freshly prepared mixture, at time zero and after 35 days storage at RT or 40° C.
- FIG. 10 shows the result of whole genome amplification assay using either lyophilized reagent or the “wet” mixture.
- Ten ng of human genomic DNA was used as template material, with a 90 minutes amplification reaction at 30° C. It was expected that greater than 4 ⁇ g of DNA should be produced in 90 minutes.
- Pico Green assay robust amplification was detected, even with lyophilized reagent that had been stored at 40° C. for 35 days. Phi29 DNA polymerase was successfully stabilized in lyophilized format.
- RNA is made using a DNA template, by a DNA-dependent RNA polymerase, such as T7 RNA polymerase.
- IVTT In vitro transcription
- the resulting RNA molecules can then be used for in vitro translation of proteins, or hybridization reactions such as northern blots, southern blots, microarray analysis and microinjections.
- the IVT formulation used for generating the lyophilized reagent includes 40 mM Tris pH 8.0, 10 mM MgCl 2 , 4 mMspermidine, 10 mM DTT, 50 ⁇ g/ml BSA, 10 mM NaCl, 0.5 mM ATP, 0.5 mM CTP, 0.5 mM GTP, 0.5 mM UTP, 2 U RNA Guard, 10 U T7 RNA Polymerase (GE Healthcare), 6.25% FICOLLTM 400, 6.25% FICOLLTM 70, 10% Melezitose.
- the prepared formulation was dispensed into 8-well strip tubes in 25 ⁇ l aliquots and lyophilized according to Example 1 and Table 2. Dried reagent cakes were tested using control DNA from the Roche SP6/T7 IVT kit. In parallel, IVT reaction was carried out using the Roche SP6/T7 IVT kit.
- a ⁇ 1000 base pair transcript is produced using the lyophilized reagent as well as the Roche kit ( FIG. 11 ). Therefore, the reagents necessary for transcription was successfully lyophilized in the presence of excipients and could be rehydrated in the proper reaction volume in the presence of a DNA template to generate an RNA transcript.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
- This application is a filing under 35 U.S.C. § 371 and claims priority to international patent application number PCT/US2007/078376 filed Sep. 13, 2007, published on Mar. 27, 2008, as WO 2008/036544, which claims priority to U.S. provisional patent application Nos. 60/845,307 filed Sep. 18, 2006 and 60/887,364 filed Jan. 31, 2007; the entire disclosures of which are incorporated herein by reference in their entireties.
- This invention relates to the long-term storage of biological materials and reagents in a glassy, porous state. In particular, it relates to methods of making these materials and reagents using a multi-well plate and the storage thereof.
- Few biologically active materials are sufficiently stable so that they can be isolated, purified, and then stored in solution at room temperature. Typically, biological reagents are stored in a glycerol solution which is maintained at temperatures of 4° C., −20° C., or −70° C. They may be stored in bulk and then combined with other reagents before use.
- In preparing reagents for convenient and efficient testing of biological samples, it is frequently important to obtain dry chemical blends in uniform, discreet amounts. One type of carrier or filler which has been used to stabilize biological reagents is glass-forming filler materials. The biological reagent solutions are incorporated into the glass-forming filler materials (which are water soluble or a water-swellable substance). They are then dried to produce a glassy composition which immobilizes and stabilizes the biological reagent. For examples of glass-forming filler materials for stabilizing biological reagents see U.S. Pat. No. 5,098,893; U.S. Pat. No. 5,200,399 and U.S. Pat. No. 5,240,843.
- Carbohydrates such as glucose, sucrose, maltose or maltotriose are an important group of glass-forming substances. Other polyhydroxy compounds can be used such as carbohydrate derivatives like sorbitol and chemically modified carbohydrates. Another important class of glass-forming substances are synthetic polymers such as polyvinyl pyrrolidone, polyacrylamide, or polyethyleneimine.
- Further examples of glass-forming substances include sugar copolymers such as those sold by GE Healthcare under the registered trademark FICOLL™. FICOLL™ has molecular weights of 5,000 to 1,000,000 and contains sucrose residues linked through ether bridges to bifunctional groups (U.S. Pat. No. 3,300,474). Such groups may be an alkylene of 2, 3 or more carbon atoms but not normally more than 10 carbon atoms. The bifunctional groups serve to connect sugar residues together. These polymers may, for example, be made by reaction of sugar with a halohydrin or bis-epoxy compound.
- Stabilized biological materials in a glassy matrix of carbohydrate polymers, can be prepared, either by freeze-drying (Treml et al. U.S. Pat. No. 5,593,824; Franks and Hatley U.S. Pat. No. 5,098,893) or by vacuum drying (Walker et al. U.S. Pat. No. 5,565,318). These water-soluble reagents are convenient to use for complex molecular biology applications. This approach is particularly useful for reagent systems composed of enzymes, nucleotides and other components dispensed in single-use aliquots. Reconstitution of the glassy matrix delivers buffered enzymes for applications including DNA amplifications and DNA sequencing.
- There are currently a number of dried molecular biology products on the market. However, some of these are made by a process that is rather cumbersome, and involves extensive manual work. Other products require refrigeration when dried. There is a need for an improved process for the generation of ambient temperature dried reagents.
- In a first aspect of the invention, it is provided a method of making a dried reagent preparation. The method comprises the steps of: providing an aqueous solution of at least one buffered biological reagent; mixing a glass forming filler material with the buffered reagent solution to form a mixture wherein the concentration of the filler material is sufficient to facilitate formation of a glassy, porous composition; dispensing a predetermined amount of the mixture into wells of a multi-well container; drying the mixture in the container to form the dried reagent preparation; wherein the reagent preparation is water soluble and has a Tg sufficient for room temperature stability. The mixture is preferably a homogeneous solution.
- In one embodiment of the invention, the dried reagent preparation is collected into a reagent bottle for prolonged room temperature storage.
- In another embodiment of the invention, the dried reagents are stored in the multi-well container, with the top of the container sealed with a sealing tape for prolonged storage. Optionally, the sealing tape is heat-activated.
- The multi-well container according to the invention can be a silica mould or a polystyrene plate. When the multi-well container is a polystyrene plate, the invention further comprises placing the polystyrene plate on a metal mould prior to lyophilizing, so that the outside wall of each well of the polystyrene plate is in close contact with a well of said metal mould for efficient heat transfer. We discovered that this improves the drying process and produces dried reagents of improved integrity.
- In another aspect of the invention, the present invention provides a dried biological reagent composition made according to the above methods.
- The reagent composition made according to the invention is water soluble and has a Tg sufficient for room temperature stability. Preferably, the reagent composition has structural integrity.
- The biological reagent composition is capable of completely dissolving in 25 μl of aqueous solution in less than 1 minute, preferably 30 seconds. The reagent composition preferably has a moisture content of less than 10%.
- The reagent composition may have at least one reagent which is unstable when alone in an aqueous solution at room temperature. The reagent composition may also comprise a plurality of reagents which may or may not react with each other when in aqueous solution at room temperature.
- It is therefore an objective and advantage of the present invention to provide a dried biological reagent composition and methods of making the same.
- These and still other objects and advantages of the invention will be apparent from the description below. However, this description is only of the preferred embodiments. The claims, therefore, should be looked to in order to assess the whole scope of the invention.
-
FIG. 1 shows a process work-flow of the method for making a dried reagent preparation according to an embodiment of the invention. -
FIG. 2 shows from the top left: a 384-well polystyrene plate that is used in the method of making a dried reagent preparation according to an embodiment of the invention; top right: standard curve showing different amounts of lambda DNA as template with starting concentration of 10 million copies to 1000 copies including a no template control; bottom left: dried reagent preparation cake/cube made from the 384-well polystyrene plate, stored in a plastic bottle; bottom right: the amplification plot showing that the dried reagent preparation is successfully used in the Lambda DNA real-time qPCR amplification reactions. -
FIG. 3 shows from the top left: a 96-well silica mould that is used in the method of making a dried reagent preparation according to an embodiment of the invention; top right: standard curve showing different amounts of lambda DNA as template with starting concentration of 10 million copies to 1000 copies including a no template control; bottom left: dried reagent tablets made from the 96-well silica mould, stored in a plastic bottle; bottom right: the amplification plot showing that the dried reagent preparation is successfully used in the Lambda DNA real-time qPCR amplification reactions. -
FIG. 4 shows a 96-well PCR plate containing PCR formulation goes into a metal holder before lyophilizing. -
FIG. 5 shows room temperature stable PCR reagents made according to an embodiment of the invention in different formats. Top left: dried PCR mix in a bottle. Top right: dried PCR mix in 96-well plate. Bottom left: dried PCR mix in 384-well plate. Bottom right: dried PCR mix in 96-well perforated plate. -
FIG. 6 shows stability of dried PCR reagents made according to an embodiment of the invention. Dried PCR mix was used for qPCR of Lambda DNA. Similar performance was noticed with (1) the ‘wet’ formulation bead mix (upper left), (2) dried cakes made using current protocol (upper right), and (3) PURE TAQ READY-TO-GO™ (RTG) PCR beads from GE Healthcare (lower left). Lower right: Ct values and PCR efficiency for the above mentioned three reactions in triplicates. Both the Ct values and PCR efficiency values of the new format and the puRe Taq RTG beads are comparable. -
FIG. 7 shows stability of dried PCR reagents made according to an embodiment of the invention. Dried PCR mix was stored at 40° C. and Room Temperature (RT) for 8 days. The dried reagents were used for qPCR of Lambda DNA, with similar performance. Top left: dried PCR reagent cakes stored at RT. Top right: dried PCR reagent cakes stored at 40° C. Bottom left: puRe Taq RTG beads (GE Healthcare) stored at RT. Bottom right: puRe Taq RTG beads stored at 40° C. -
FIG. 8 shows Ct values and PCR efficiency for the above mentioned four reactions in duplicates. Both the Ct values and PCR efficiency values of the current format and the puRe Taq RTG beads are comparable at 40° C. and room temperature. -
FIG. 9 shows the results of real-time PCR reactions according to one example of the invention. Upper left panel: real-time PCR using lyophilized reagents including the TaqMan primers and probe. Lower left panel: Lyophilized reagent control (TaqMan primers and probe were not lyophilized, other reagents were lyophilized as in Example 1). Upper right panel: Commercial puRe Taq RTG bead control (All the other reagents were not lyophilized). When puRe Taq RTG reactions were used to make a standard curve while treating all other reactions as unknowns the reactions with equivalent amounts of template DNA fell on the standard curve (Lower right panel, “X” denotes the “unknowns”). -
FIG. 10 shows that the Phi29 DNA polymerase is stable in the lyophilized form. Whole genome amplification assay using either lyophilized reagent or the “wet” mixture was performed. Robust amplification was detected, even with lyophilized reagent that had been stored at 40° C. for 35 days. -
FIG. 11 shows successful transcription of a DNA template using lyophilized IVT reagent (A, B, C) as compared to conventional “wet” kit (Roche IVT). ntc: no template control. - Many biological reagents are suitable for storage by the method of the present invention. The biological reagent compositions of the present invention are particularly suitable for performing a wide variety of analytical procedures which are beneficially or necessarily performed on blood plasma or diluted plasma. The analytical procedures will generally require that the blood plasma be combined with one or more reagent spheres so that some optically detectible change occurs in the plasma which may be related to measurement of a particular component or characteristic of the plasma. Preferably, the plasma will undergo a reaction or other change which results in a changing color, fluorescence, luminescence or the like, which may be measured by conventional spectrophotometers, fluorometers, light detectors, etc. In some cases, immunoassays and other specific binding assays may be performed.
- A still further category of biological reagents to which the present invention is applicable is protein and peptides, including derivatives thereof such as glycoproteins. Such proteins and peptides may be any of: enzymes, transport proteins (for example hemoglobin, immunoglobulins, hormones, blood clotting factors and pharmacologically active proteins or peptides).
- Another category of biological reagents to which the invention is applicable comprises nucleosides, nucleotides (such as deoxynucleotides, ribonucleotides and dideoxynucleotides), dinucleotides, oligonucleotides and also enzyme cofactors, whether or not these are nucleotides. Enzyme substrates in general are also biological reagents to which the invention may be applied.
- The biological reagent for stabilization in storage may be isolated from a natural source, animal, plant, fungal or bacterial, or may be produced by and isolated from cells grown by fermentation and artificial culture. Such cells may or may not be genetically transformed cells.
- Another development of this invention is to store more than one reagent of a reacting system in a glass reagent sphere. This can be useful for materials which will be required to be used together in, for example, an assay or a diagnostic kit.
- Storing the reagents in a single glassy preparation provides them in a convenient form for eventual use. For instance, if an assay requires a combination of a substrate or cofactor and an enzyme, two or all three could be stored in a glassy reagent sphere in the required concentration ratio and be ready for use in the assay.
- If multiple reagents are stored, they may be mixed together in an aqueous emulsion and then incorporated together into a glass. Alternatively, they may be incorporated individually into separate glasses which are then mixed together.
- When multiple reagents are stored as a single composition (which may be two glasses mixed together) one or more of the reagents may be a protein, peptide, nucleoside, nucleotide, or enzyme cofactor. It is also possible that the reagents may be simpler species. For instance, a standard assay procedure may require pyruvate and NADH to be present together. Both can be stored alone with acceptable stability. However, when brought together in an aqueous solution they begin to react. If put together in required proportions in the glassy reagent sphere, they do not react and the glass can be stored. By react we mean any biochemical reaction.
- The preferred biological reagents of the present invention are enzymes and cofactors that provide a reagent system to detect, amplify, modify or sequence nucleic acids. Such enzymes include but are not limited to DNA polymerases (e.g. Klenow), T7 DNA polymerase or various thermostable DNA polymerases such as Taq DNA polymerase; AMV or murine reverse transcriptase, T4 DNA ligase, T7, T3, SP6 RNA polymerase, Phage Phi29 DNA polymerase, and restriction enzymes. Cofactors include nucleotides, oligonucleotides, DNA, RNA, required salts for enzyme activity (e.g. magnesium, potassium and sodium), and salts required for buffer capacity. Buffer salts provide a proper pH range and aid stability. Some buffers which may be used include Tris pH 7.6-8.3.
- Any potential biological reagents may be evaluated using a protocol according to Example 1, infra. Thus, suitable biological reagents are rendered stable in the reagent sphere as determined by a functionality test like that in Example 1.
- Examples of glass forming filler materials which may be used in the present invention include carbohydrates such as FICOLL™, sucrose, glucose, trehalose, melezitose, DEXTRAN™, and mannitol; proteins such BSA, gelatin, and collagen; and polymers such as PEG and polyvinyl pyrrolidone (PVP). The glass forming filler materials are preferably FICOLL™ polymer, BSA, sucrose, DEXTRAN™, or combinations thereof. A most preferred glass forming filler material for use in the present invention is FICOLL™ polymer.
- The formulation of a high viscosity mixture of biological reagent, glass forming filler material, and water is determined by an iterative process. First, one determines final as used concentrations desired of the system. The concentrations are normally stated in terms of molarity. Each biological reagent may have different formulations. Secondly, these concentrations are converted to a weight/dose basis for solids and a volume/dose basis for liquids.
- Third, an initial value is chosen for the percent solids concentration of the high viscosity mixture and the desired mixture volume. A 55% solids concentration has been shown to work well. Above a 62% solids concentration the mixture is too stringy for dispensing. If an emulsion is desired, below a 52% solids concentration the mixture is too thin and dries clear and hard. If a semi-emulsion is desired, a lower limit of 10% is permissible. By “% solids” we mean (weight solids times 100) div (weight liquid plus weight solids).
- The mixture will dry hard and glassy if the glass forming material is allowed to go into solution. Thus, the desired mixture is an emulsion rather than a solution. By emulsion we mean a saturated mixture such that two phases, solid and liquid, are present. For example, the present invention is a semi-emulsion of a glass forming filler material in a biological reagent/buffer solution. The presence of the solids gives the emulsion an opaque to white color. A high viscosity emulsion still forms a glass when dried, but pores are available on the surface for water to move through and speed dissolution of the dried reagent preparation. The emulsion should have a white color. If it is clear, it most likely will dry hard and glassy, and therefore, will be nonporous. By porosity we mean that the dried reagent preparation contains pockets of air bubbles which assist in the dissolution of the preparation. A preferred porosity would allow the preparation to dissolve in about 2 minutes or less.
- Another version of the invention provides a mixture of glass forming filler material and a biological reagent/buffer solution which is characterized as being a semi-emulsion. By this we mean a mixture having at least some properties of an emulsion. The semi-emulsion of the present invention may be formed by using the above iterative process to arrive at a solids concentration of about 10% to about 50%. The semi-emulsion can then be dispensed and dried to form the dried reagent preparation.
- Fourth, one calculates the number of doses that can be made using the grams of glass forming material per dose from the second step.
- Fifth, using the number of doses and the weight per dose ratios from the second step, one determines the weights in volumes of the other components. Finally, using the weights and volumes determined in the fifth step, one calculates the percent solids of the final mixture. If the final percent solids of the mixture are out of the desired range, one repeats the third through sixth steps with another initial value until the final value is in the correct range.
- Any potential glass forming material may be evaluated using a protocol according to the iterative process described above. Thus, a suitable glass forming material produces a reagent preparation having an acceptable hardness, size, shape, Tg, porosity, solubility, and stability.
- Examples of multi-well containers for making the dried reagent preparation include a polystyrene plate, a silica mould, or the like. Preferably, the multi-well plate is one that has a standard dimension and layout that enables to use standard thermal cyclers for applications like PCR.
- Generally, the multi-well containers comprise two regions, a well field and a border. The border can be of any dimension, shape, or thickness, but preferably forms a multi-well platform with outer dimensions that are similar to those of a standard 96- or 384-well commercial microtiter plate, whose dimensions are approximately 85.5 mm in width by 127.75 mm in length.
- Typically, the plate contains a number of hollows arranged in a grid. These hollows are known as wells and act as reaction vessels for individual reactions, or storage containers for individual samples. Wells will be arranged in two-dimensional linear arrays on the multi-well platform. However, the wells can be provided in any type of array, such as geometric or non-geometric arrays. The number of wells can be a multiple of 96 within these ranges, preferably the square of an integer multiplied by 96.
- Wells in the commercial plates are typically designed with standard spacing. A 96-well plate has twelve columns and eight rows with 9 mm spacing between the centers of adjacent wells. A 384-well plate has twenty-four columns and sixteen rows with 4.5 mm spacing between the centers of adjacent wells. A 1536-well plate has forty-eight columns and thirty-two rows with 2.25 mm spacing between the centers of adjacent wells. Microtiter plates constituting one half of the above format are also in use. Also available are strips of wells that have similar spacing between the centers of adjacent wells. Multi-well containers having these dimensions can be compatible with robotics and instrumentation, such as multi-well platform translocators and readers as they are known in the art.
- The materials for manufacturing the multi-well platform will typically be polymeric, since these materials lend themselves to mass manufacturing techniques. Preferably, polymers are selected that are known to have low fluorescence or other properties. Various methods in the art can be used to confirm that selected polymers possess the desired properties. Polymeric materials can particularly facilitate plate manufacture by molding methods known in the art and developed in the future, such as insert or injection molding.
- An alternative to the polymeric plates are silica moulds in a 96-well and 384-well formats. As shown in the Examples infra, a 96-well perforated silica molded plate can be used for dispensing and lyophilizing the reagents. The advantage here is the dried reagents should be easily removed from the mould after lyophilization.
- A typical formulation (using DNA labeling formulation as the example) is made as follows:
- All reagents used are typically autoclaved or filter sterilized (preferably a 0.25 μm filter) before use. Formulations are made and stored on ice until dispensed. For 200 mls (enough for 20,000 single dose preparation) of a DNA labeling formulation, 15 g each of
FICOLL™ 400 and FICOLL™ 70 and 20 g melezitose are added to approximately 90 ml of sterile water and mixed on a stir plate until dissolved. - 50 ml of a 20× concentrated DNA labeling buffer (200 mM Tris pH 7.5, 200 mM MgCl2 1M NaCl) is added along with 10 mls of a 10 mg/ml BSA solution. One ml each of 100 mM ATP, GTP, and TTP are added. Once all the reagents are in solution the formulation is stored on ice or under refrigeration until it is to be used for dispensing. Just before use, 400 Ku of Klenow fragment DNA polymerase is added (minimum concentration of stock should be 100 Ku/ml in order to keep the glycerol concentration below 1% in the final preparation). Also just before use, 1200 A 260 Units of d(N)9 primer is added. Before adding to the formulation, the primer should be heated at 65° C. for 7 minutes and quickly cooled on ice. After addition of the enzyme and primer, the final volume should be brought to 200 ml with sterile water. The density of the final solution will be 1.14 g/ml.
- The final volume per dose dispensed of the reagent homogeneous solution is often small, such as 5-30 μl, preferably 10 μl, to allow a working volume of 10-100 μl when the reagent preparation is dissolved in a working solution.
- A predetermined amount of homogeneous solution is dispensed into each well of a multi-well container, typically using a liquid dispensing robot (96 well/384 well pins). The solution is dispensed in a volume ranging from 4 μl to 20 μl but preferably 10 μl.
- The sample dispensed can be dried by freeze-drying or lyophilization. A suitable drying program produces a reagent preparation having an acceptable hardness, size, shape, Tg, porosity, solubility, and stability.
- A typical successful freeze-drying profile is shown below in Table 1.
-
TABLE 1 Temperature (° C.) Vacuum (mTorr) Time (min.) Comment −46 atmosphere 60 hold −46 40 600 hold −36 40 250 ramp −36 40 300 hold 0 40 400 ramp 0 40 300 hold 28 40 233 ramp 28 40 240 hold - A preferred method of drying is by way of lyophilization. The dispensed reagents are successfully dried in a 96- or 384-well polystyrene plate. Surprisingly, when the polystyrene thin-walled plate was placed onto and in direct contact with a fitted metal plate holder, the drying process works better and no foam or flakes of the dried reagent observed compared to the plates dried without metal holders (
FIGS. 1 and 4 ). Direct contact of the outside wall of a polystyrene well (tube) with the metal well of the metal plate holder indirectly enhances the metal shelf contact area, which in turn achieves a better heat transfer to the samples. A silica mould, on the other hand, has a thick wall and flat bottom for each well, and the lyophilization process in a silica mould works reasonably well without the use of a metal holder. This is probably due to the better contact of the mould with the freeze-dryer shelf and the heat transfer properties of the silica. A preferred lyophilization profile is shown below in Tables 2. Note that the samples are frozen in the freeze-drier for 1 hour at −46° C. before running the following program. -
TABLE 2 Temperature (° C.) Vacuum (mTorr) Time (min.) Comment −46 100 600 hold −36 100 250 ramp −36 100 300 hold 0 100 400 ramp 0 100 300 hold 28 100 233 ramp 28 100 360 hold Post Heat: 28 100 2000 hold - We successfully prepared stable biological reagents in tablet, cylinder and cube formats in polystyrene and silica based plates or moulds. Our technology allows the stabilization of temperature sensitive protein and nucleic acid molecules into single-dose format, stable at ambient temperatures. The single-dose format (bead or cake) can contain the pre-dispensed buffer, salt, detergent and nucleotide, etc. needed for the specific assay, in which the molecules are used. These enzymes and combinations can be used for a variety of molecular biology applications, including but not limited to PCR, RT-PCR, real time PCR, whole genome amplification, in vitro transcription and cDNA synthesis applications.
- Our method eliminated the need to freeze drop the reagent mix into liquid nitrogen or onto a cold surface, yet the dried reagents maintain good structural integrity. The method has fewer steps in the manufacturing process. The dried reagent preparations can be stored in the plates or moulds directly when properly sealed and this significantly reduces the manufacturing and packaging costs. Alternatively, the dried reagents can be removed from silica moulds as tablets and from polyfiltronics 96-well plates as cubes and stored in sealed containers, i.e. capped bottles.
- Sealing of the plate or mould can be achieved by: lid, tape, heat activated tape etc. In one embodiment of the invention, sealing of the plates is achieved by heat activation sealing using AbGene's Thermo-Seal and Easy-Peel sheets.
- A reagent preparation of the present invention is room temperature stable. By “room temperature stable,” we mean that the preparation can be stored at 22° C. for greater than 6 months with less than 20% loss of enzymatic activity as compared to the activity measured after the reagents are first dried.
- A reagent preparation of the present invention has a glass transition temperature (Tg) of at least 10° C. A typical Tg of the reagent preparation is 40° C. A Tg of at least 40° C. will guarantee stability at room temperature (22° C.). A preferred Tg is 45° C. The glass transition temperature is the temperature above which the viscosity of a glassy material drops rapidly and the glassy material turns into a rubber, then into a deformable plastic which at even higher temperatures turns into a fluid.
- The glass transition temperature is used as an important indicator of stability of the preparation. At temperatures below or near the Tg the sample remains as a stable glass. As the temperature rises above the Tg, the sample becomes a rubber and is less stable. The Tg is measured using differential scanning calorimetry. 2-5 mg (1-2 spheres crushed) of sample are put into an aluminum pan. The Tg of the sample is determined by subjecting the sample to a controlled temperature program from 0° C. to 100° C. at a rate of 10° C./min. The heat flow to and from the sample is measured and expressed as a shift in the baseline. The Tg is expressed as the temperature at the midpoint of this baseline shift.
- A typical porosity will allow dissolution of the sphere in 20 μl of water in 1 minute or less. A preferred porosity will allow dissolution in 30 seconds or less.
- Our method of making glassified biological reagent preparation offers several advantages. The manufacturing process is greatly simplified. The reagent mixture is dispensed directly into wells of a multi-well plate, which has a standard format as the commercial microtiter plate. This eliminated the need to freeze the reagent droplets in liquid nitrogen or on a cold surface. The dispensed mixture is then frozen, lyophilized in the well, and can be stored in the well too. This eliminated the need of moving the beads or the cakes from a drying pan into a storage container. Because the dried composition can be stored in the multi-well plate, the composition can be used in a subsequent workflow that is automated. Robotic systems can be used for processing the plates.
- In addition, the compositions made are stable at ambient temperature. This saves cost on shipping (no dry-ice shipping), eliminates the need for freezer storage and shortens the reagent preparation time (no thawing). It offers convenience for the subsequent user. Most of the assay-related components could be pre-dispensed and stabilized into the single dose format. It saves the user time and plastic consumable costs for preparing the reagents master mix. It also offers increased reproducibility and reliability, as it reduced risk of contamination and errors. The composition is prepared with pre-dispensed reactions. This minimizes sample handling and pipetting steps, thus reducing the risk of contamination and pipetting errors by the user.
- The present examples are provided for illustrative purposes only, and should not be construed as limiting the scope of the present invention as defined by the appended claims. All references given below and elsewhere in the present specification are hereby included herein by reference.
- The biological reagent formulation, in this case, a reagent mixture for PCR is prepared according to standard protocol. In short, the formulation of the 10 μl sphere contains 25 mM Tris-HCl (pH 9.0 at room temperature), 125 mM KCl, 3.75 mM MgCl2, 0.5 mM dNTP's, 0.6 mg/ml BSA, 3.5 units of rTaq DNA polymerase, and the glass-forming filler material comprising synthetic polymers FICOLL™ 400 (6.25%), FICOLL™ 70 (6.25%) and the secondary carbohydrate Melezitose (10%). All reagents are typically autoclaved or filter sterilized before use. Formulations are made and stored on ice until mixed and dispensed into polystyrene plates or silica moulds. Final formulation consists of glass forming filler material, BSA, dNTPs, and rTaq DNA polymerase and salts as described above.
- The final volume per dose of the reagent homogeneous solution was 10 μl. This allowed a working volume for PCR of 25 μl. The reagent was dispensed using an automatic pipette into a 384-well polystyrene plate.
- The 384-well plate was placed on top of the pre-cooled (−46° C.) Vertis freeze-dryer shelf for about 60 minutes to freeze the reagents. The frozen reagents were then subjected to the primary and subsequent secondary drying processes, according to the process described in Table 2 supra.
- The plate containing the dried reagents was stored in a re-sealable pouch containing desiccant as an integrated package by simply covering the plate with an adhesive cover or lid or a thermo seal. Alternatively, the dried reagents were removed from the plate as dried reagent tablets or cubes and were stored in a bottle and the bottles were stored in re-sealable pouch containing desiccant.
- Stability of the dried reagent composition was tested by real-time PCR amplification of Lambda DNA and comparing the amplification profile with that of commercial product (puRe Taq RTG beads; GE Healthcare). The primers used for the testing are SEQ ID NO: 1 (5′-GGT TAT CGA AAT CAG CCA CAG CGC C-3′) and SEQ ID NO: 2 (5′-GAT GAG TTC GTG TCC GTA CAA CTG G-3′). The real-time PCR amplification results are shown in
FIG. 2 . - In
FIG. 2 , a 384-well polystyrene plate is shown on the upper left side, which was used for making the dried reagent composition. The dried reagent tablets were stored in a plastic bottle (bottom left side) and stored at room temperature for about a week in a resalable pouch containing the desiccant. A 384-well plate containing the dried reagents is shown on the upper left side and is covered with the adhesive seal. The standard curve of different dilutions of lambda DNA template is shown on the upper right side. The real-time amplification curves of different dilutions of lambda DNA is shown on the bottom right side. In conclusion, the success in real-time PCR amplification reactions proof that the dried reagent composition is stable. - The biological reagent formulation and the glass-forming filler material are prepared and mixed together according to Example 1. About 20 μl reagent mixture was dispensed using an automatic pipette into a 96-well silica mould (
FIG. 3 , upper left side). The silica mould was placed in a pre-cooled (−46° C.) Vertis freeze-dryer for about 60 minutes to freeze the reagents. The frozen reagents were then subjected to the primary and subsequent secondary drying processes, according to the process described in Table 2 supra. - The dried reagents could be stored in the mould as an integrated package by simply covering the mould with an adhesive seal and by placing the plate in aluminum pouch containing desiccant. Alternatively, the dried reagents were removed from the mould as dried reagent cakes and were stored in a bottle containing desiccant.
- Stability of the dried reagent composition was tested by real-time PCR amplification of Lambda DNA according to Example 1, and comparing the amplification profile with that of commercial product (puRe Taq RTG beads; GE Healthcare). The results are shown in
FIG. 3 . - In
FIG. 3 , a 96-well silica mould is shown on the upper left side, which is used for making the dried reagent composition. The dried reagent cubes were stored in a plastic bottle (bottom left side) for a week in a re-sealable pouch containing the desiccant before performing the lambda DNA functional test. The standard curve of different dilutions of lambda DNA template is shown on the upper right side. The real-time PCR amplification plots of the different dilutions of lambda is shown on the bottom right side. In conclusion, the success in real-time PCR amplification reactions proof that the dried reagent composition is stable. - The biological reagent formulation and the glass-forming filler material were prepared and mixed together according to Example 1. 10 μl reagent mixture was dispensed using an liquid dispensing robot (
FIG. 1 , bottom left side). The 96-well plate was placed on a 96-well metal holder (FIG. 4 ). The 96-well plate with the metal holder was placed on top of the pre-cooled (−46° C.) Vertis freeze-dryer shelf for about 60 minutes to freeze the reagents. The frozen reagents were then subjected to the primary and subsequent secondary drying processes, according to the process described in Table 2 supra. - The dried reagents could be stored in the 96-well plate as an integrated package by simply covering the plate with an adhesive seal or a lid or a thermoseal with the help of a heat sealer. Lambda DNA real-time PCR functional test was performed with the freshly prepared “wet” formulation and the dried reagents along with puRe Taq RTG beads. The sealed plates were stored at room temperature or in a 40° C. incubator for 8 days in a pouch containing desiccant. Stability of the dried reagent composition was tested by real-time PCR amplification of Lambda DNA (according to Example 1) and comparing the amplification profile with that of commercial product (puRe Taq RTG beads; GE Healthcare). The results are shown in
FIGS. 6 , 7 and 8. -
FIG. 6 shows Lambda qPCR with 96-well dried PCR cakes and comparison with the ‘wet’ formulation and the puRe Taq RTG beads. The figure shows stability of dried PCR reagents made according to an embodiment of the invention. Real-time PCR amplifications were performed with different concentrations of Lambda DNA starting from 10 million copies to 10 copies as template along with a no template control. Similar performance in terms of Ct values and PCR efficiency (bottom left table) was noticed with current format (upper right), puRe Taq RTG beads (lower left) and the ‘wet’ formulation (upper left). -
FIG. 7 shows stability of dried PCR reagents made according to an embodiment of the invention. Dried PCR mix was stored at 40° C. or Room Temperature (RT) for 8 days, then used for qPCR of Lambda DNA. The reagent made according to present invention achieved similar performance, as compared to commercial puRe Taq RTG bead. Top left: dried PCR reagent cakes stored at RT. Top right: dried PCR reagent cakes stored at 40° C. Bottom left: puRe Taq RTG beads stored at RT. Bottom right: puRe Taq RTG beads stored at 40° C.FIG. 8 shows the Ct values and the PCR efficiency for the current format reagents and the puRe Taq RTG beads at room temperature and 40° C. - Real-time PCR is become an increasingly popular assay platform for gene expression analysis. One method for detection of amplified product in real time PCR utilizes a dual labelled single stranded (ss) DNA probe that is homologous to a specific portion of the template. The fluorescent modifications on this probe serve as a reporter (FAM) and quencher (TAMRA). In the presence of a single stranded template, the probe anneals to the template but does not emit fluorescent signal because of close proximity of the reporter dye to the quencher dye. When Taq DNA polymerase amplifies DNA from the template the 5′-3′ exonuclease activity of the enzyme cleaves the labelled probe annealed to the template, releasing the quencher dye allowing for the reporter to fluoresce. The fluorescent signal is then recorded by the real time instrument.
- We demonstrate here that PCR primers along with a TaqMan probe can be lyophilized in the presence of excipients and can be used in real-time PCR without loss of function relative to reactions in which the primers and probe are not lyophilized. The formulation used to make a 2.5× concentrated formulation for assaying β-actin includes: 25 mM Tris pH 9, 125 mM KCl, 3.75 mM MgCl2, 0.6 mg/ml BSA, 0.5 mM dNTPs, 0.25 U/μl rTaq, 0.05
% Tween 20, 0.05% NP-40, 1.5 μM β-actin Fwd primer (SEQ ID NO: 3: 5′-TCA CCC ACA CTG TGC CCA TCT ACG A-3′), 1.5 μM β-actin Rev primer (SEQ ID NO: 4: 5′-CAG CGG AAC CGC TCA TTG CCA ATG G-3′), 1 μM β-action probe (SEQ ID NO: δ: 5′-FAM-ATG CCC-N (TAMRA) CCC CCA TGC CAT C CTG CGT p-3′), 6.25% FICOLL™ 70, 6.25% FICOLL™ - Ten microliter aliquots of the formulation were pipetted into 96-well plate and lyophilized. Single dried cakes were rehydrated in a final volume of 25 μl with varying amounts of human genomic DNA template. Real-time PCR reactions were carried out with an ABI 7900 Fast Real Time instrument. Reactions were compared to a similar formulation as above that did not contain the primers and probe. For these latter reactions the primers and probe were added during PCR reaction set up. In addition, commercially available puRe Taq RTG beads were used as an additional control.
-
FIG. 9 shows the results of these reactions. Upper left panel: real-time PCR using lyophilized reagents including the TaqMan primers and probe. Lower left panel: Lyophilized reagent control (The primers and probe were not included in the lyophilized formulation, but added prior to the real-time PCT reaction). Upper right panel: Commercial puRe Taq RTG bead control (All the other reagents were not lyophilized). All reactions produced equivalent amplification profiles, R2 values and slopes. When puRe Taq RTG reactions were used to make a standard curve while treating all other reactions as unknowns the reactions with equivalent amounts of template DNA fell on the standard curve (Lower right panel). Our results demonstrate that TaqMan primers and probe are amenable to RTG incorporation. - Phi29 DNA polymerase is widely used for whole genome amplification as well as rolling circle amplification. We lyophilized this enzyme in a formulation that enables whole genome amplification. Our analyses demonstrate that the lyophilized formulation has the same activity as the “wet” formulation in performing whole genome amplification.
- GENOMIPHI™ HY (High Yield) DNA amplification kit (GE Healthcare) contains all the components necessary for whole genome amplification by isothermal stand displacement amplification. The starting material for GENOMIPHI™ reactions can be purified DNA or non-purified cell lysates. Microgram quantities of DNA can be generated from nanogram amounts of starting material in only a few hours. Typical DNA yields from a GENOMIPHI™ HY reaction are 40-50 μg per 50 μl reaction, with an average product length of greater than 10 kb. DNA replication is extremely accurate due to the
proofreading 3′-5′ exonuclease activity of the enzyme. - GENOMIPHI™ reaction mixture was prepared including Phi29 DNA polymerase, random hexamers, dNTPs and the GENOMIPHI™ HY reaction buffer along with the stabilizers FICOLL™ 70,
FICOLL™ 400, Melezitose and BSA, as a 2× mix. Ten μl volume aliquots of the mixture were dispensed into 12-well PCR strip tubes. The dispensed products were lyophilized as a cake using VirTis freeze-drier. The dried products were stored at either room temperature or at 40° C. for 35 days. Whole genome amplification was successfully performed with these products using as low as 10 ng of human genomic DNA. This was compared with whole genome amplification using freshly prepared mixture, at time zero and after 35 days storage at RT or 40° C. -
FIG. 10 shows the result of whole genome amplification assay using either lyophilized reagent or the “wet” mixture. Ten ng of human genomic DNA was used as template material, with a 90 minutes amplification reaction at 30° C. It was expected that greater than 4 μg of DNA should be produced in 90 minutes. Using Pico Green assay, robust amplification was detected, even with lyophilized reagent that had been stored at 40° C. for 35 days. Phi29 DNA polymerase was successfully stabilized in lyophilized format. - Transcription is a vital biological process regularly carried out by cells of all types in which RNA is made using a DNA template, by a DNA-dependent RNA polymerase, such as T7 RNA polymerase. In vitro transcription (IVT) is this same process done outside the cell in a test tube generating transcripts of choice by the end user. The resulting RNA molecules can then be used for in vitro translation of proteins, or hybridization reactions such as northern blots, southern blots, microarray analysis and microinjections.
- We successfully generated lyophilized ambient temperature stable IVT reagents where all components required for RNA production minus the template were lyophilized in the presence of excipients. This greatly simplifies the IVT reaction such that the end user only needs to add template DNA and water to start the reaction
- The IVT formulation used for generating the lyophilized reagent includes 40 mM Tris pH 8.0, 10 mM MgCl2, 4 mM Spermidine, 10 mM DTT, 50 μg/ml BSA, 10 mM NaCl, 0.5 mM ATP, 0.5 mM CTP, 0.5 mM GTP, 0.5 mM UTP, 2 U RNA Guard, 10 U T7 RNA Polymerase (GE Healthcare), 6.25
% FICOLL™ 400, 6.25% FICOLL™ 70, 10% Melezitose. The prepared formulation was dispensed into 8-well strip tubes in 25 μl aliquots and lyophilized according to Example 1 and Table 2. Dried reagent cakes were tested using control DNA from the Roche SP6/T7 IVT kit. In parallel, IVT reaction was carried out using the Roche SP6/T7 IVT kit. - As expected, a ˜1000 base pair transcript is produced using the lyophilized reagent as well as the Roche kit (
FIG. 11 ). Therefore, the reagents necessary for transcription was successfully lyophilized in the presence of excipients and could be rehydrated in the proper reaction volume in the presence of a DNA template to generate an RNA transcript. - While the preferred embodiment of the present invention has been shown and described, it will be obvious in the art that changes and modifications may be made without departing from the teachings of the invention. The matter set forth in the foregoing description and accompanying drawings is offered by way of illustration only and not as a limitation. The actual scope of the invention is intended to be defined in the following claims when viewed in their proper perspective based on the prior art.
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/439,274 US8900525B2 (en) | 2006-09-18 | 2007-09-13 | Preparation of glassified biological reagents |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84530706P | 2006-09-18 | 2006-09-18 | |
US88736407P | 2007-01-31 | 2007-01-31 | |
PCT/US2007/078376 WO2008036544A1 (en) | 2006-09-18 | 2007-09-13 | Preparation of glassified biological reagents |
US12/439,274 US8900525B2 (en) | 2006-09-18 | 2007-09-13 | Preparation of glassified biological reagents |
Publications (2)
Publication Number | Publication Date |
---|---|
US20090325263A1 true US20090325263A1 (en) | 2009-12-31 |
US8900525B2 US8900525B2 (en) | 2014-12-02 |
Family
ID=38988318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/439,274 Active 2029-07-31 US8900525B2 (en) | 2006-09-18 | 2007-09-13 | Preparation of glassified biological reagents |
Country Status (7)
Country | Link |
---|---|
US (1) | US8900525B2 (en) |
EP (1) | EP2063866B2 (en) |
JP (1) | JP5989957B2 (en) |
CN (1) | CN104774924B (en) |
AU (1) | AU2007297484B2 (en) |
CA (1) | CA2663440C (en) |
WO (1) | WO2008036544A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9688979B2 (en) * | 2013-06-11 | 2017-06-27 | Biocartis Nv | Biomolecule drying process for long-term storage |
US9976173B2 (en) | 2012-10-09 | 2018-05-22 | Advandx, Inc. | Devices, compositions and methods pertaining to microscopic analysis of microorganisms and other analytes of interest |
US10294068B2 (en) * | 2016-04-21 | 2019-05-21 | Canon Kabushiki Kaisha | Image forming apparatus |
US10982290B2 (en) * | 2014-07-25 | 2021-04-20 | Global Life Sciences Solutions Operations UK Ltd | Screening and monitoring the progression of type 2 diabetes by the molecular identification of human gut flora using FTA as a faecal collection device |
CN113430251A (en) * | 2021-06-16 | 2021-09-24 | 成都博奥晶芯生物科技有限公司 | Concentration method of constant-temperature amplification reagent and integrated biochip |
US20220301596A1 (en) * | 2019-08-22 | 2022-09-22 | Donaldson Company, Inc. | Gas replenishment component for an enclosure |
WO2023167945A1 (en) * | 2022-03-01 | 2023-09-07 | Argonaut Manufacturing Services, Inc. | Devices that include a dried reagent:substrate complex and methods for generating such complexes and devices |
EP4117870A4 (en) * | 2020-03-09 | 2024-07-03 | Idexx Lab Inc | Method for removing interfering components of a liquid sample prior to dispensing same on a chemical reagent test slide |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2688174C (en) | 2008-12-19 | 2018-08-07 | F. Hoffmann-La Roche Ag | Dry composition of reaction compounds with stabilized polymerase |
AU2010258716B2 (en) * | 2009-06-12 | 2015-11-12 | Perkinelmer Health Sciences, Inc. | Compositions and methods for dehydrated storage of on-board reagents in microfluidic devices |
CN102803483B (en) * | 2009-06-12 | 2014-04-30 | 精密公司 | Rehydratable matrices for dry storage of TAQ polymerase in a microfluidic device |
EP2418286A1 (en) | 2010-08-10 | 2012-02-15 | QIAGEN GmbH | Improved method for isothermal amplification of nucleic acids |
JP5798631B2 (en) | 2010-10-04 | 2015-10-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Method for cell lysis in RT-PCR reaction buffer |
CA2810316A1 (en) | 2010-10-04 | 2012-04-12 | F. Hoffmann-La Roche Ag | Method for cell lysis and pcr within the same reaction vessel |
GB201219137D0 (en) * | 2012-10-24 | 2012-12-05 | Ge Healthcare Uk Ltd | Direct nucleic acid amplification kit, reagent and method |
WO2014100725A1 (en) | 2012-12-21 | 2014-06-26 | Micronics, Inc. | Portable fluorescence detection system and microassay cartridge |
KR20150096788A (en) | 2012-12-21 | 2015-08-25 | 마이크로닉스 인코포레이티드. | Low elasticity films for microfluidic use |
GB201301457D0 (en) * | 2013-01-28 | 2013-03-13 | Fluorogenics Ltd | Freeze-dried composition |
EP2994532B1 (en) | 2013-05-07 | 2017-11-15 | Micronics, Inc. | Methods for preparation of nucleic acid-containing samples using clay minerals and alkaline solutions |
JP6484222B2 (en) | 2013-05-07 | 2019-03-13 | マイクロニクス, インコーポレイテッド | Devices for nucleic acid preparation and analysis |
WO2014182844A1 (en) | 2013-05-07 | 2014-11-13 | Micronics, Inc. | Microfluidic devices and methods for performing serum separation and blood cross-matching |
US9868944B2 (en) | 2014-12-19 | 2018-01-16 | Roche Molecular Systems, Inc. | Reaction mixtures |
JP6651709B2 (en) * | 2015-04-16 | 2020-02-19 | 大日本印刷株式会社 | Microplate containing reagent and method for producing the same |
WO2017160835A1 (en) | 2016-03-14 | 2017-09-21 | The Regents Of The University Of Michigan | A surface tension mediated lyo-processing technique for preservation of biologics |
AU2018270296B2 (en) | 2017-05-19 | 2022-11-10 | Gen-Probe Incorporated | Dried compositions containing flap endonuclease |
JP2021521232A (en) * | 2018-04-16 | 2021-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Methods for stabilizing proteins containing pharmaceuticals using meglumine salts |
CA3097061A1 (en) * | 2018-04-16 | 2019-10-24 | Merck Patent Gmbh | Viscosity reduction of highly concentrated protein formulations |
JP6756358B2 (en) * | 2018-12-14 | 2020-09-16 | 大日本印刷株式会社 | Microplate containing reagent and its manufacturing method |
CN114058684A (en) * | 2020-07-31 | 2022-02-18 | 广东菲鹏生物有限公司 | Freeze-drying protection formula of reagent for nucleic acid amplification, product, preparation method and application thereof |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3300474A (en) * | 1964-02-12 | 1967-01-24 | Pharmacia Ab | Sucrose ether copolymerizates |
US4498782A (en) * | 1981-05-29 | 1985-02-12 | Science Research Center, Inc. | Assembly for determining light transmissiveness of a fluid |
US5053332A (en) * | 1989-07-24 | 1991-10-01 | Cook Richard B | Agarose beads, preferably incorporating biological materials |
US5098893A (en) * | 1989-02-16 | 1992-03-24 | Pafra Limited | Storage of materials |
US5200399A (en) * | 1990-09-14 | 1993-04-06 | Boyce Thompson Institute For Plant Research, Inc. | Method of protecting biological materials from destructive reactions in the dry state |
US5240843A (en) * | 1988-11-11 | 1993-08-31 | Cranfield Biotechnology Ltd. | Enzyme stabilisation |
US5565318A (en) * | 1994-09-02 | 1996-10-15 | Pharmacia Biotech, Inc. | Room temperature stable reagent semi-spheres |
US5593824A (en) * | 1994-09-02 | 1997-01-14 | Pharmacia Biotech, Inc. | Biological reagent spheres |
US5962244A (en) * | 1998-05-07 | 1999-10-05 | Tularik Inc. | High-throughput in vitro assays for modulators of peptidyl transferase |
US6485913B1 (en) * | 1999-03-10 | 2002-11-26 | Sequenom, Inc. | Systems and methods for performing reactions in an unsealed environment |
US20030119042A1 (en) * | 2001-03-12 | 2003-06-26 | Biotools Biotechnological & Medical Laboratories, S.A. | Process for preparing stabilized reaction mixtures which are totally or partially dried, comprising at least one enzyme, reaction mixtures and kits containing said mixtures |
US6977722B2 (en) * | 2001-06-29 | 2005-12-20 | Meso Scale Technologies, Llc. | Assay plates, reader systems and methods for luminescence test measurements |
US7048915B2 (en) * | 2000-10-19 | 2006-05-23 | Cellfree Sciences Co., Ltd. | Composition for cell-free protein synthesis |
US20060172928A1 (en) * | 2002-07-04 | 2006-08-03 | Micronas Gmbh | Composition and method for stabilizing of biomolecules |
US20070190163A1 (en) * | 2006-01-24 | 2007-08-16 | Malaknov Michael P | Technology for preparation of macromolecular microspheres |
US7303869B2 (en) * | 2001-07-17 | 2007-12-04 | Northwestern University | Solid-phase reactions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1785726A1 (en) * | 1999-02-17 | 2007-05-16 | Carbozyme NT Ltd | Combinatioral complex carbohydrate libraries and methods for the manufacture and uses thereof |
EP1425090A2 (en) * | 2001-09-07 | 2004-06-09 | Corning Incorporated | MICROCOLUMN−PLATFORM BASED ARRAY FOR HIGH−THROUGHPUT ANALYSIS |
JP4042394B2 (en) * | 2001-12-04 | 2008-02-06 | 味の素株式会社 | Manufacturing method of block-like freeze-dried foods |
-
2007
- 2007-09-13 AU AU2007297484A patent/AU2007297484B2/en active Active
- 2007-09-13 US US12/439,274 patent/US8900525B2/en active Active
- 2007-09-13 CA CA2663440A patent/CA2663440C/en active Active
- 2007-09-13 CN CN201510105699.2A patent/CN104774924B/en active Active
- 2007-09-13 WO PCT/US2007/078376 patent/WO2008036544A1/en active Application Filing
- 2007-09-13 EP EP07842408.2A patent/EP2063866B2/en active Active
- 2007-09-13 JP JP2009528470A patent/JP5989957B2/en active Active
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3300474A (en) * | 1964-02-12 | 1967-01-24 | Pharmacia Ab | Sucrose ether copolymerizates |
US4498782A (en) * | 1981-05-29 | 1985-02-12 | Science Research Center, Inc. | Assembly for determining light transmissiveness of a fluid |
US5240843A (en) * | 1988-11-11 | 1993-08-31 | Cranfield Biotechnology Ltd. | Enzyme stabilisation |
US5098893A (en) * | 1989-02-16 | 1992-03-24 | Pafra Limited | Storage of materials |
US5053332A (en) * | 1989-07-24 | 1991-10-01 | Cook Richard B | Agarose beads, preferably incorporating biological materials |
US5200399A (en) * | 1990-09-14 | 1993-04-06 | Boyce Thompson Institute For Plant Research, Inc. | Method of protecting biological materials from destructive reactions in the dry state |
US5565318A (en) * | 1994-09-02 | 1996-10-15 | Pharmacia Biotech, Inc. | Room temperature stable reagent semi-spheres |
US5593824A (en) * | 1994-09-02 | 1997-01-14 | Pharmacia Biotech, Inc. | Biological reagent spheres |
US5962244A (en) * | 1998-05-07 | 1999-10-05 | Tularik Inc. | High-throughput in vitro assays for modulators of peptidyl transferase |
US6485913B1 (en) * | 1999-03-10 | 2002-11-26 | Sequenom, Inc. | Systems and methods for performing reactions in an unsealed environment |
US7048915B2 (en) * | 2000-10-19 | 2006-05-23 | Cellfree Sciences Co., Ltd. | Composition for cell-free protein synthesis |
US20030119042A1 (en) * | 2001-03-12 | 2003-06-26 | Biotools Biotechnological & Medical Laboratories, S.A. | Process for preparing stabilized reaction mixtures which are totally or partially dried, comprising at least one enzyme, reaction mixtures and kits containing said mixtures |
US6977722B2 (en) * | 2001-06-29 | 2005-12-20 | Meso Scale Technologies, Llc. | Assay plates, reader systems and methods for luminescence test measurements |
US7303869B2 (en) * | 2001-07-17 | 2007-12-04 | Northwestern University | Solid-phase reactions |
US20060172928A1 (en) * | 2002-07-04 | 2006-08-03 | Micronas Gmbh | Composition and method for stabilizing of biomolecules |
US20070190163A1 (en) * | 2006-01-24 | 2007-08-16 | Malaknov Michael P | Technology for preparation of macromolecular microspheres |
Non-Patent Citations (1)
Title |
---|
Aaron Equipment Company (2013) from http:// www.aaronequipment.com/usedequipment/dryers-drying-equipment * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9976173B2 (en) | 2012-10-09 | 2018-05-22 | Advandx, Inc. | Devices, compositions and methods pertaining to microscopic analysis of microorganisms and other analytes of interest |
US9688979B2 (en) * | 2013-06-11 | 2017-06-27 | Biocartis Nv | Biomolecule drying process for long-term storage |
US10982290B2 (en) * | 2014-07-25 | 2021-04-20 | Global Life Sciences Solutions Operations UK Ltd | Screening and monitoring the progression of type 2 diabetes by the molecular identification of human gut flora using FTA as a faecal collection device |
US10294068B2 (en) * | 2016-04-21 | 2019-05-21 | Canon Kabushiki Kaisha | Image forming apparatus |
US20220301596A1 (en) * | 2019-08-22 | 2022-09-22 | Donaldson Company, Inc. | Gas replenishment component for an enclosure |
US12057144B2 (en) * | 2019-08-22 | 2024-08-06 | Donaldson Company, Inc. | Gas replenishment component for an enclosure |
EP4117870A4 (en) * | 2020-03-09 | 2024-07-03 | Idexx Lab Inc | Method for removing interfering components of a liquid sample prior to dispensing same on a chemical reagent test slide |
CN113430251A (en) * | 2021-06-16 | 2021-09-24 | 成都博奥晶芯生物科技有限公司 | Concentration method of constant-temperature amplification reagent and integrated biochip |
WO2023167945A1 (en) * | 2022-03-01 | 2023-09-07 | Argonaut Manufacturing Services, Inc. | Devices that include a dried reagent:substrate complex and methods for generating such complexes and devices |
Also Published As
Publication number | Publication date |
---|---|
AU2007297484A1 (en) | 2008-03-27 |
EP2063866A1 (en) | 2009-06-03 |
JP2010503410A (en) | 2010-02-04 |
JP5989957B2 (en) | 2016-09-07 |
EP2063866B1 (en) | 2013-08-07 |
CN104774924B (en) | 2021-04-13 |
EP2063866B2 (en) | 2017-08-23 |
CA2663440C (en) | 2014-07-08 |
AU2007297484B2 (en) | 2013-07-18 |
WO2008036544A1 (en) | 2008-03-27 |
US8900525B2 (en) | 2014-12-02 |
CA2663440A1 (en) | 2008-03-27 |
CN104774924A (en) | 2015-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8900525B2 (en) | Preparation of glassified biological reagents | |
JP6097862B2 (en) | Compositions and methods for dehydrating and storing on-board reagents in microfluidic devices | |
US20050069898A1 (en) | Lyophilized beads containing mannitol | |
EP0820521B1 (en) | Biological reagent spheres | |
AU2005258951B2 (en) | Method for stabilising reagents which are useful for nucleic acid amplification | |
US9057674B2 (en) | Reagent reservoir system for analytical instruments | |
US5565318A (en) | Room temperature stable reagent semi-spheres | |
US20080193946A1 (en) | Universal and Target Specific Reagent Beads for Nucleic Acid Amplification | |
WO2006036848A2 (en) | Multiple bead reagent system for protein based assays with optimized matrices | |
WO2017184028A1 (en) | Stabilized mixture of reagents for molecular diagnostics | |
KR20180103945A (en) | The dried amplification composition | |
US20240092986A1 (en) | Compositions on plasma-treated surfaces | |
US20130280695A1 (en) | Method, device and test kit for molecular-biological reactions | |
CN101516337A (en) | Preparation of glassified biological reagents | |
US20100015628A1 (en) | Ambient temperature stable chemical/biological reagents on membranes or filters | |
US20230138093A1 (en) | Lyophilized reagents | |
CN117597453A (en) | Compositions, methods, kits, cartridges, and systems for sequencing reagents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551) Year of fee payment: 4 |
|
AS | Assignment |
Owner name: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC, MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:GE HEALTHCARE BIO-SCIENCES CORP.;REEL/FRAME:053648/0854 Effective date: 20190930 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |